110 related articles for article (PubMed ID: 36950960)
1. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
[TBL] [Abstract][Full Text] [Related]
2. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Rimini M; Loi E; Rizzato MD; Pressiani T; Vivaldi C; Gusmaroli E; Antonuzzo L; Martinelli E; Garajova I; Giordano G; Lucchetti J; Schirripa M; Cornara N; Rossari F; Vitiello F; Amadeo E; Persano M; Piva VM; Balsano R; Salani F; Pircher C; Cascinu S; Niger M; Fornaro L; Rimassa L; Lonardi S; Scartozzi M; Zavattari P; Casadei-Gardini A
Target Oncol; 2024 Mar; 19(2):223-235. PubMed ID: 38345693
[TBL] [Abstract][Full Text] [Related]
3. Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.
Wheless M; Agarwal R; Goff L; Lockney N; Padmanabhan C; Heumann T
Curr Treat Options Oncol; 2024 Jan; 25(1):127-160. PubMed ID: 38177560
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.
Storandt MH; Jin Z; Mahipal A
Onco Targets Ther; 2024; 17():383-394. PubMed ID: 38774819
[TBL] [Abstract][Full Text] [Related]
6. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
7. Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
Ottaiano A; Santorsola M; Diana A; Belli A; Lentini Graziano ML; Orefice J; Patrone R; Di Mauro A; Scognamiglio G; Tatangelo F; De Bellis M; Piccirillo M; Fiore F; Stilo S; Tarotto L; Correra M; Di Lorenzo S; Capuozzo M; Avallone A; Silvestro L; Bianco A; Granata V; Federico P; Montesarchio V; Daniele B; Izzo F; Nasti G
Cancer Med; 2024 Feb; 13(4):e6892. PubMed ID: 38457226
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma.
Chrystle M; Sanyo D
BMJ Case Rep; 2023 Mar; 16(3):. PubMed ID: 36863754
[TBL] [Abstract][Full Text] [Related]
9. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint inhibitors for the Treatment of Biliary Tract Cancer.
Casak SJ; Kumar V; Song C; Yuan M; Amatya AK; Cheng J; Mishra-Kalyani PS; Tang S; Lemery SJ; Auth D; Davis G; Kluetz PG; Pazdur R; Fashoyin-Aje LA
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38856639
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Yoo C; Hyung J; Chan SL
Liver Cancer; 2024 Apr; 13(2):119-135. PubMed ID: 38638168
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials.
Karasic TB; Eads JR; Goyal L
JCO Precis Oncol; 2023 Apr; 7():e2200573. PubMed ID: 37053534
[No Abstract] [Full Text] [Related]
13. Update on the Screening, Diagnosis, and Management of Cholangiocarcinoma.
Kodali S; Connor AA; Brombosz EW; Ghobrial RM
Gastroenterol Hepatol (N Y); 2024 Mar; 20(3):151-158. PubMed ID: 38680168
[TBL] [Abstract][Full Text] [Related]
14. Rational development of combination therapies for biliary tract cancers.
Harding JJ; Khalil DN; Fabris L; Abou-Alfa GK
J Hepatol; 2023 Jan; 78(1):217-228. PubMed ID: 36150578
[TBL] [Abstract][Full Text] [Related]
15. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Sarantis P; Tzanetatou ED; Ioakeimidou E; Vallilas C; Androutsakos T; Damaskos C; Garmpis N; Garmpi A; Papavassiliou AG; Karamouzis MV
Am J Transl Res; 2021; 13(12):13246-13260. PubMed ID: 35035673
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Peripheral Neuropathy Associated with Immune Checkpoint Inhibitors: Case Report and Review of Literature.
Bonilla CE; Ávila V
Case Rep Oncol Med; 2024; 2024():8212943. PubMed ID: 38596399
[TBL] [Abstract][Full Text] [Related]
17. Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer.
Fung S; Syed YY
Target Oncol; 2024 Jan; 19(1):129. PubMed ID: 38019360
[No Abstract] [Full Text] [Related]
18. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M; Fornaro L; Lonardi S; Niger M; Lavacchi D; Pressiani T; Lucchetti J; Giordano G; Pretta A; Tamburini E; Pirrone C; Rapposelli IG; Diana A; Martinelli E; Garajová I; Simionato F; Schirripa M; Formica V; Vivaldi C; Caliman E; Rizzato MD; Zanuso V; Nichetti F; Angotti L; Landriscina M; Scartozzi M; Ramundo M; Pastorino A; Daniele B; Cornara N; Persano M; Gusmaroli E; Cerantola R; Salani F; Ratti F; Aldrighetti L; Cascinu S; Rimassa L; Antonuzzo L; Casadei-Gardini A
Liver Int; 2023 Aug; 43(8):1803-1812. PubMed ID: 37452505
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in cholangiocarcinoma.
Beri N
Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
